Gyre Therapeutics Inc (GYRE): Bathi resik saben saham sajrone 12 wulan pungkasan

Simbol lan logo merek Gyre Therapeutics (GYRE)

The stability of Gyre Therapeutics, Inc. (GYRE) is underpinned by its high authority in fibrosis therapy and positive dynamics in trailing twelve-month net income per share, where -0.27 represents the latest metric reading. Growth is driven by synergy between US and Chinese scientists, while the operational foundation is based on liquidity and drug sales in Asia to fund new research.

GYRE (Gyre Therapeutics, Inc.) riwayat Bathi resik saben siji saham sajrone rolas wulan pungkasan saka 21.02.2024 nganti 18.11.2026

Rincian analitis perusahaan Gyre Therapeutics, Inc.

- rega saham lan target rega konsensus:
Analisis dhasar perusahaan:GYRE - Gyre Therapeutics
Produk sing diprodhuksi Gyre Therapeutics Corp.

The investment attractiveness of Gyre Therapeutics, Inc. (GYRE) is based on the monetization of liver fibrosis drugs, which creates resources for new research. This indicator calculates net income allocated per share over a rolling year, allowing a real-time assessment of capital efficiency and fundamental business stability via the trailing 12-month earnings per share, eliminating the impact of reporting seasonality.